isavuconazonium

Isavuconazonium is a second-generation triazole antifungal used to treat serious fungal infections, specifically invasive aspergillosis and invasive mucormycosis in adults and children. It acts as a prodrug of isavuconazole, which inhibits the synthesis of ergosterol—a key component of the fungal cell membrane—by blocking the cytochrome P-450-dependent enzyme lanosterol 14-alpha-demethylase (CYP51). This disruption weakens the fungal cell membrane, leading to cell death. Isavuconazonium offers high water solubility for intravenous use and good oral bioavailability. It was developed as an alternative to other azole antifungals that require cyclodextrin for IV administration, thus reducing nephrotoxicity risk. The drug was approved by the FDA in 2015 and marketed under the brand name Cresemba[1][2][3][5][6].

Brand names

Cresemba

Other names

isavuconazonium sulfateisavuconazole prodrug